Valerio Therapeutics (ALVIO) AI Stock Analysis

• Market Cap: €84.91M
• Dividend Yield: N/A
• Average Volume (3M): 2.78M
• Price to Earnings (P/E): ―
• Beta (1Y): -1.54
• Revenue Growth: -3.12%
• EPS Growth: 30.49%
• Country: FR
• Employees: 38
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 488,847,870
• 10 Day Avg. Volume: 5,642,672
• 30 Day Avg. Volume: 2,775,793
• PEG Ratio: -0.07
• Price to Book (P/B): -1.29
• Price to Sales (P/S): 6.44
• P/FCF Ratio: -0.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: €0.00 ▼(-100.00% Downside)

Valerio Therapeutics' overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, negative profitability, and high leverage. While technical analysis shows some bullish momentum, the negative P/E ratio and lack of dividend yield detract from its valuation appeal. The absence of earnings call data and corporate events limits additional insights.

Valerio Therapeutics Business Overview & Revenue Model

Company Description

Valerio Therapeutics (ALVIO) is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer and other serious diseases. The company operates primarily in the biotechnology sector, leveraging advanced research and development to create novel drug candidates aimed at improving patient outcomes. Valerio Therapeutics is dedicated to addressing unmet medical needs through its pipeline of targeted therapies and is committed to advancing healthcare through scientific innovation.

How the Company Makes Money

Valerio Therapeutics generates revenue primarily through the commercialization of its pharmaceutical products, including sales from approved therapies and potential royalties from licensed drugs. Additionally, the company may pursue partnerships and collaborations with larger pharmaceutical firms, providing funding in exchange for rights to develop and market specific drug candidates. Research grants and funding from governmental and private institutions may also contribute to its revenue streams, particularly for early-stage developments. As the company advances its pipeline and achieves regulatory approvals, it stands to benefit from milestone payments from partners, further enhancing its financial growth.

Valerio Therapeutics Financial Statement Overview

Summary

Valerio Therapeutics faces significant financial challenges, including declining revenues, negative profitability margins, and high leverage. The negative equity and cash flow issues further highlight financial instability. The company needs to address its operational inefficiencies and improve its financial health to ensure long-term sustainability.

Income Statement

Valerio Therapeutics shows declining revenue with a negative revenue growth rate of -5.08% in the latest year. The gross profit margin is relatively strong at 71.39%, but the company suffers from significant net losses, reflected in a net profit margin of -13.35%. The EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The company has a negative stockholders' equity, leading to a concerning debt-to-equity ratio of -1.50. This indicates financial instability and high leverage. The return on equity is positive at 2.68%, but this is due to the negative equity, which is not a healthy sign.

Cash Flow

Valerio Therapeutics has negative operating and free cash flows, with a free cash flow growth rate of -22.25%. The operating cash flow to net income ratio is negative, indicating cash flow issues. However, the free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is somewhat aligned with net income.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.79M	1.80M	1.44M	4.06M	1.78M
Gross Profit	1.28M	1.27M	929.00K	3.69M	1.43M
EBITDA	-12.06M	-18.44M	-17.04M	-5.86M	2.33M
Net Income	-23.93M	-20.34M	-19.56M	-5.94M	1.09M
Balance Sheet
Total Assets	17.93M	35.27M	43.09M	53.06M	46.51M
Cash, Cash Equivalents and Short-Term Investments	1.18M	6.82M	14.59M	17.89M	14.52M
Total Debt	13.44M	9.00M	10.09M	9.94M	6.26M
Total Liabilities	26.19M	20.47M	20.82M	20.12M	17.47M
Stockholders Equity	-8.93M	14.80M	22.27M	32.94M	29.04M
Cash Flow
Free Cash Flow	-12.78M	-18.78M	-9.93M	-8.71M	-4.80M
Operating Cash Flow	-12.46M	-18.60M	-9.44M	-8.57M	-4.68M
Investing Cash Flow	-1.39M	-177.00K	-409.00K	-66.00K	6.01M
Financing Cash Flow	4.21M	10.76M	6.46M	11.98M	7.48M

Valerio Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALVIO, the sentiment is Positive. The current price of 0.06 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.09, and below the 200-day MA of 0.07, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 58.30 is Neutral, neither overbought nor oversold. The STOCH value of 42.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALVIO.

Valerio Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALVIO	50 Neutral	€84.91M	―	―	―	-3.12%	30.49%
ALTHX	41 Neutral	€22.71M	―	―	―	―	10.30%
ALTME	37 Underperform	€8.52M	-0.78	-917.95%	―	―	―